Studies on the molecular recognition between bioactive peptides and angiotensin-converting enzyme

Journal of Molecular Recognition

Volumn 22, Issue 2, 2009, Pages 162-168

  Pina, A S ^a   Roque, A C A ^a  

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

Angiotensin converting enzyme; Bioactive peptides; Docking; Hypertension; IPP; Molecular recognition; Nutraceuticals; VPP

Indexed keywords

ACE PROTEIN, HUMAN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ISOLEUCYL PROLYL PROLINE; ISOLEUCYL-PROLYL-PROLINE; LACTOKININS; MILK PROTEIN; OLIGOPEPTIDE; VALYL PROLYL PROLINE; VALYL-PROLYL-PROLINE; ZINC;

ARTICLE; CHEMISTRY; ENZYME ACTIVE SITE; HUMAN; HYDROGEN BOND; METABOLISM; PROTEIN BINDING; PROTEIN CONFORMATION; X RAY CRYSTALLOGRAPHY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; HUMANS; HYDROGEN BONDING; MILK PROTEINS; OLIGOPEPTIDES; PEPTIDYL-DIPEPTIDASE A; PROTEIN BINDING; PROTEIN CONFORMATION; ZINC;

EID: 63449118442     PISSN: 09523499     EISSN: 10991352     Source Type: Journal    
DOI: 10.1002/jmr.905     Document Type: Article

References (34)

1. Acharya KR, Sturrock D, Riordan JF, Ehlers MRW, 2003. ACE revisited: a new target for structure-based drug design. Nat. Rev. Drug Discov. 2: 891-902.
2. Andújar-Sánchez M, Cámara-Artigas A, Jara-Pérez V. 2004. A calorimetric study of the binding of lisinopril, enalaprilat and captopril to angiotensin-converting enzyme. Biophys. Chem. 111: 183-189.
3. Clare DA, Swaisgood HE. 2000. Bioactive milk peptides: a prospectus. J. Dairy Sci. 83: 1187-1195.
4. Corradi HR, Chitapi I, Sewell BT, Georgiadis D, Dive V, Sturrock ED, Acharya KR. 2007. The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380. Biochemistry 46: 5473-5478.
5. Corradi HR, Schwager SLU, Nchinda AT, Sturrock D, Acharya KR. 2006. Crystal structure of the N domain of human somatic angiotensin l-converting enzyme provides a structural basis for domain-specific inhibitor design. J. Moi. Biol. 357: 964-974.
6. FitzGerald RJ, Murray AM, Walsh DJ. 2004. Hypotensive peptides from milk proteins. J. Nutr. 134: 980S-988S,
7. Georgiadis D, Beau F, Czarny J, Cotton J, Yiotakis A, Dive V. 2003. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin. Circ. Res. 93: 148-154.
8. Kim HM, Shin DR, Yoo OJ, Lee H, Lee J. 2003. Crystal structure of Drosophila angiotensin I-converting enzyme bound to Captopril and lisinopril, FEBS Lett. 538: 65-70.
9. Korhonen H, Pihlanto A. 2003. Food-derived bioactive peptides- opportunities for designing future foods. Curr. Pharm. Des. 9: 1297-1308.
10. Korhonen H, Pihlanto A. 2006. Bioactive peptides: production and functionality. Int. Dairy J. 16: 945-960.
11. Li GH, Le G.W., Shi YH, Shrestha S. 2004. Angiotensin l-converting enzyme inhibitory peptides derived from food proteins and their physiological and pharmacological effects. Nutr. Res. 24: 469-486.
12. Lopez-Fandino R, Otte J, Van Camp J. 2008. Physiological, chemical and technological aspects of milk-protein-derived peptides with antihypertensive and ACE-inhibitory activity. Int. Dairy J. 16: 1277-1293.
13. Maes W, Van Camp J, Vermeirssen V, Hemeryck M, Ketelslegers JM, Schrezenrneir J, Van Oostveldt P, Huyghebaert A. 2004. Influence of the lactokinin Ala-Leu-Pro-Met-His-lle-Arg (ALPMHIR) on the release of endothelial cells, Regul. Pept. 118: 105-109,
14. Molegro. 2007. Molegro Virtual Docker - User Manual. Molegro 2007.
15. Natesh R, Schwager SLU, Evans HR, Sturrock ED, Acharya KR. 2004. Structural details on the binding of antihypertensive drug Captopril and enalaprilat to human testicular angiotensin l-converting enzyme. Biochemistry 43: 8718-8724.
16. Natesh R, Schwager SLU, Sturrock ED, Acharya KR. 2003. Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature 421: 551-554.
17. Otte J, Shalaby SM, Zakora M, Pripp AH, El-Shabrawy SA. 2007. Angiotensin-converting enzyme inhibitory activity of milk protein hydro-lysates: effect of substrate, enzyme and time of hydrolysis, Int. Dairy J. 17: 488-503.
18. Pan D, Luo Y, Tanokura M. 2005. Antihypertensive peptides from skimmed milk hydrolysate digested by cell-free extract of Lactobacillus helveticus JCM1004. Food Chem. 91: 123-129.
19. Pripp AH, Isaksson T, Stepaniak L, Sorhaug T. 2004. Quantitative structure-activity relationship modelling of ACE-inhibitory peptides derived from milk proteins. Eur. Food Res. Technol. 219: 579-583.
20. Redelinghuys P, Nchinda AT, Chibale K, Sturrock D. 2006. Novel keto-methylene inhibitors of angiotensin l-converting enzyme (ACE): inhibition and molecular modelling. Biol. Chem. 387: 461-466.
21. Rieger K, Saez-Servent N, Papet M, Wdzieczak-Bakala J, Morgat J, Thierry J, Voelter W, Lenfant M. 1993. Involvement of human plasma angiotensin l-converting enzyme in the degradation of the haemoregu-latory peptide N-acetyl-seryl-aspartyl-lysyl-proline. Biocbem. J. 296: 373-378.
22. Roufik S, Gauthier SF, Turgeon SL. 2007. Physicochemical characterization and in vitro digestibility of β-lactoglobulin/β-Lg f142-148 complexes. Int. Dairy J. 17:471-480.
23. Smacchi E, Gobbetti M. 2000. Bioactive peptides in dairy products: synthesis and interaction with proteolytic enzymes. Food Microbiol. 17: 129-141.
24. Spinola M, Finckenberg P, Korpela R, Vapaatalo H, Nurminen M, 2002. Effect of long-term intake of milk products on blood pressure in hypertensive rats. J. Dairy Res. 69: 103-111.
25. Sturrock ED, Natesh R, Van Rooyen JM, Acharya KR. 2004. Structure of angiotensin l-converting enzyme. Cell. Mol. Life Sci. 61:2677-2686.
26. Thomas FG (ed.). 2000. Medicinal Chemistry - An Introduction. Wiley: Chichester, UK.
27. Thomsen R, Christensen MH. 2006. MolDock: a new technique for high-accuracy molecular docking. J. Med. Chem. 49: 3315-3321.
28. Tzakos AG, Galanis AS, Spyroulias GA, Cordopatis P, Manessi-Zoupa E, Gerothanassis IP. 2003. Structure-function discrimination of the island C- catalytic domains of human angiotensin-converting enzyme: implications for Cl~ activation and peptide hydrolysis mechanisms. Protein Eng. 16: 993-1003.
29. Tzakos AG, Gerothanassis IP. 2005. Domain-selective ligand-binding modes and atomic level pharmacophore refinement in angiotensin l-converting enzyme (ACE) inhibitors. ChemBioChem 6: 1089-1103.
30. Vermeirssen V, Van Camp J, Verstraete W. 2002. Optimisation and validation of an angiotensin-converting enzyme inhibition assay for the screening of bioactive peptides. J. Biochem. Biophys. Methods 51: 75-87.
31. Walsh DJ, Bernard H, Murray AM, MacDonald J, Pentzien A-K, Wright GA, Wal J-M, Struthers AD, Meisel H, FitzGerald RJ. 2004. In vitro generation and stability of the lactokinin β-lactoglobulin fragment (142-148). J. Dairy Sci. 87: 3845-3857.
32. Wei L, Clauser E, Alhenc-Gelas F, Corvol P. 1992. The two homologues domains of human angiotensin l-converting enzyme interact differently with competitive inhibitors, J. Biol. Chem. 267; 13398-13405.
33. Wu J, Aliko RE, Nakai S. 2006a. Structural requirements of angiotensin l-converting enzyme inhibitory peptides: quantitative structure-activity relationship study of di- and tripeptides. J. Agric. Food Chem. 54: 732-738.
34. Wu J, Aluko RE, Nakai S. 2006b. Structural requirements of angiotensin l-converting enzyme inhibitory peptides: quantitative structure-activity relationship modeling of peptides containing 4-10 amino acid residues. QSAR Comb. Sci. 10: 873-880.